Yahoo
HKSE - Delayed Quote HKD

MicroPort CardioFlow Medtech Corporation (2160.HK)

1.280 0.000 (0.00%)
As of August 31 at 4:08:46 PM GMT+8. Market Open.
Chart Range Bar
Loading chart for 2160.HK
  • Previous Close 1.280
  • Open 1.435
  • Bid 1.290 x --
  • Ask 1.300 x --
  • Day's Range 1.280 - 1.435
  • 52 Week Range 0.930 - 6.400
  • Volume 1,161,000
  • Avg. Volume 318,148
  • Market Cap (intraday) 1.629B
  • Beta (5Y Monthly) 0.24
  • PE Ratio (TTM) --
  • EPS (TTM) -0.310
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 6.94

MicroPort CardioFlow Medtech Corporation, together with its subsidiaries, researches, develops, manufactures, and sells medical devices for the treatment of structural heart disease and cardiac rhythm management in China, Europe, the Middle East, Africa, Asia, North America, and internationally. The company offers VitaFlow, a transcatheter aortic valve system; VitaFlow Liberty, a transcatheter aortic valve retrievable and controllable bend delivery system; Alwide, a plus valve balloon dilation catheter; AccuSniper, a double-layer balloon dilation catheter, Angelguide, an advanced pre-shaped ultra-hard guidewire; and AnchorMan, a left atrial appendage occlusion and guidance system. It also provides various active, mitral, and tricuspid valve products; left atrial appendage closure products; surgical accessories; low and high-voltage CRM products; leads and accessories; patient monitoring products; and arrhythmia diagnostic devices. In addition, the company offers clinical solutions, including aortic stenosis and atrial fibrillation-related stroke prevention. Further, it is involved in the manufacturing of raw materials for medical devices treating valvular heart diseases; and properties management. The company was founded in 2009 and is headquartered in Shanghai, China.

www.cardioflowmedtech.com

1,415

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/5/2026, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

2160.HK
78.31%
HANG SENG INDEX (^HSI)
3.48%

1-Year Return

2160.HK
77.54%
HANG SENG INDEX (^HSI)
4.61%

3-Year Return

2160.HK
86.09%
HANG SENG INDEX (^HSI)
40.05%

5-Year Return

2160.HK
94.62%
HANG SENG INDEX (^HSI)
0.53%

Analyst Insights

View More

Analyst Price Targets

6.27
6.94 Average
1.280 Current
7.61 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -32.99%

  • Return on Assets (ttm)

    -2.36%

  • Return on Equity (ttm)

    -6.66%

  • Revenue (ttm)

    57.04M

  • Net Income Avi to Common (ttm)

    -18.82M

  • Diluted EPS (ttm)

    -0.310

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    189.32M

  • Total Debt/Equity (mrq)

    90.64%

  • Levered Free Cash Flow (ttm)

    -100.5M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: